Blue LED-initiated selenylation produces potent anticancer compounds in cell models, suggesting therapeutic potential.
Blue LED-initiated selenylation of unsaturated acid amides with diorganyl diselenides in acetic and formic acids was shown to proceed either through a three-component conjugate addition to the double C=C bond, or via selenocyclization, depending on the N-substituent and solvent. The latter occurs as O-cyclization via the exo-trig mode to give iminolactones/lactones or as N-cyclization via the 5-exo-trig and 6-endo-trig modes to give selenyl-functionalized perhydroindolones and piperidinones, respectively. Among the synthesized compounds, the piperidinone derivative 12ea exhibited the greatest antiproliferative potency in human cervical carcinoma (HeLa) and human colorectal carcinoma (HCT-116) cells, with half-maximal inhibitory concentration (IC50) values in the micromolar range. Mechanistic studies revealed induction of apoptosis, confirmed by caspase-3/7 activation, Annexin V/propidium iodide staining, and nuclear abnormalities with γH2AX foci, consistent with DNA damage and mitotic stress. In three-dimensional spheroid models, 12ea effectively suppressed tumor-like growth and promoted apoptotic cell death. These findings identify 12ea as a promising and selective lead compound for further development in anticancer drug discovery.
No takes yet. Share an insight, caveat, or question.
Vaskevych et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: